European Medicines Agency Awards Arno Therapeutics, Inc. (ARNI) AR-42 Orphan Drug Designation
Arno Therapeutics, a clinical-stage company focused on developing products for the treatment of cancer, today announced that its investigational compound AR-42 has been granted orphan-drug designation by the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products for the treatment of neurofibromatosis type 2 (NF2), a rare genetic disorder characterized by the growth of noncancerous tumors in the brain and spinal cord, juvenile cataracts, and neurofibromas of the skin. The EMA grants orphan-drug designation for medicines designed to treat life-threatening or debilitating conditions affecting no more than five in 10,000 people, and allows the developer to obtain inspection-fee reductions, protocol…